Reviewing BIOLASE (BIOL) and Biomerica (BMRA)

Share on StockTwits

BIOLASE (NASDAQ:BIOL) and Biomerica (NASDAQ:BMRA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, dividends, analyst recommendations, profitability and earnings.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for BIOLASE and Biomerica, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BIOLASE 0 0 0 0 N/A
Biomerica 0 0 1 0 3.00

Biomerica has a consensus price target of $7.50, suggesting a potential upside of 145.10%. Given Biomerica’s higher probable upside, analysts clearly believe Biomerica is more favorable than BIOLASE.

Risk and Volatility

BIOLASE has a beta of 1.74, suggesting that its share price is 74% more volatile than the S&P 500. Comparatively, Biomerica has a beta of -0.18, suggesting that its share price is 118% less volatile than the S&P 500.

Earnings and Valuation

This table compares BIOLASE and Biomerica’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
BIOLASE $46.93 million 0.63 -$16.85 million N/A N/A
Biomerica $5.56 million 4.97 -$1.46 million ($0.17) -18.00

Biomerica has lower revenue, but higher earnings than BIOLASE.

Profitability

This table compares BIOLASE and Biomerica’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
BIOLASE -40.31% -72.43% -44.35%
Biomerica -31.75% -41.73% -34.79%

Institutional & Insider Ownership

34.8% of BIOLASE shares are held by institutional investors. Comparatively, 1.5% of Biomerica shares are held by institutional investors. 2.1% of BIOLASE shares are held by company insiders. Comparatively, 26.8% of Biomerica shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Biomerica beats BIOLASE on 8 of the 11 factors compared between the two stocks.

About BIOLASE

BIOLASE, Inc., a medical device company, develops, manufactures, markets, and sells laser systems in dentistry and medicine for patients and health care professionals in the United States and internationally. The company offers Waterlase all-tissue dental laser systems for cutting soft and hard tissues; and diode laser systems, which are used to perform soft tissue, pain therapy, and cosmetic procedures, including teeth whitening. Its dental laser systems allow dentists, periodontists, endodontists, oral surgeons, and other dental specialists to perform a range of dental procedures, such as cosmetic, restorative, and complex surgical applications. The company also markets, sells, and distributes dental imaging equipment, including three-dimensional (3D) CAD/CAM intra-oral scanners and digital dentistry software. Its dental imaging products comprise 3Shape Trios intraoral scanners, digital impression systems, and software for taking 3D scans, which are used to design crowns, study models, surgical guides for implant placement, and event orthodontic and athletic appliances. In addition, the company manufactures and sells consumable products and accessories for its laser systems, as well as markets flexible fibers and hand pieces. It sells its products primarily to dentists in general practice through its field sales force and distributor network. BIOLASE, Inc. was founded in 1984 and is headquartered in Irvine, California.

About Biomerica

Biomerica, Inc., together with its subsidiaries, develops, manufactures, and markets medical diagnostic products for the early detection and monitoring of chronic diseases and medical conditions. The company's diagnostic test kits are used to analyze blood, urine, or fecal samples from patients in the diagnosis of various diseases and other medical complications; or to measure the level of specific hormones, antibodies, antigens, or other substances, which exist in the human body in extremely small concentrations. It primarily focuses on products for gastrointestinal diseases, food intolerances, diabetes, and various esoteric tests. The company offers its products to hospital and clinical laboratories, medical research institutions, medical schools, pharmaceutical companies, chain drugstores, wholesalers, and physicians' offices, as well as to distributors. It operates in Europe, the United States, Asia, South America, the Middle East, and internationally. Biomerica, Inc. was founded in 1971 and is headquartered in Irvine, California.

Receive News & Ratings for BIOLASE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOLASE and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply